Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Elsevier Partners with the Korean Society for Molecular and Cellular Biology to Publish Molecules and Cells

Elsevier

The Korean Society for Molecular and Cellular Biology (KSMCB), one of the largest and most prominent academic societies in the field of life sciences in Korea, and Elsevier, a leader in information and analytics for customers across the global research and health ecosystems, are pleased to announce a new partnership to publish Molecules and Cells, the flagship journal of KSMCB. This English-language publication will be hosted on Elsevier’s industry-leading online platform of peer-reviewed literature, ScienceDirect, beginning January 1, 2024. Continuing as a Gold Open Access, online-only publication, all articles will be immediately and permanently free to read and download. Junho Lee, PhD, Professor, Department of Biological Sciences, Seoul National University and President of KSMCB, commented, “It is with great pleasure that I would like to announce that KSMCB has entered into a co-publishing agreement with Elsevier. The rationale behind this decision is to meet the challenges of an ever-changing publishing environment and the growing needs of society members and scientific colleagues. We will be able to take advantage of the global network and professionalism that Elsevier brings, which will result in the recognition that our journal strives to achieve on the global stage. We envision that Molecules and Cells will make a giant leap forward in the near future to becoming a premier international scientific journal of which we can all be proud.” Launched in 1990 and now in its 46th volume, Molecules and Cells has continually solidified its position as a leading journal in the fields of molecular and cellular biology. It has published articles in English from more than 30 countries on its way to becoming a globally recognized journal. Since 1995, the journal has been indexed in Web of Science/Science Citation Index-Expanded, the first Korean journal in the biological sciences to be accepted for inclusion in this service. Molecules and Cells continues its tradition of publishing excellence under the expert leadership of Editor-in-Chief Jae Bum Kim, PhD, supported by an eminent editorial board. After earning his doctoral degree in the Department of Microbiology & Molecular Genetics, Harvard University, Prof. Kim has held a number of prestigious academic appointments in Korea and the United States. He is currently Professor in the Department of Biological Sciences and serves as the Director of the Center for Adipose Tissue Remodeling, Creative Research Initiatives, Center for Studies on Structure-Function in Adipocyte at Seoul National University. Prof. Kim noted, “The editorial team, editorial board, KSMCB leadership, and I remain passionate and committed to timely publication of the highest quality scholarly work. We anticipate that Elsevier’s exceptional level of publishing expertise and professionalism will help bring the journal to a wider worldwide audience of authors and readers more efficiently and effectively, providing greater opportunities for collaboration and knowledge sharing.” The journal will expand its impact and outreach through availability via ScienceDirect, which will host 33 years of Molecules and Cells back volumes (from 1990 onwards). ScienceDirect has 1 billion annual visits and over 17,000 licenses worldwide. Manuscripts may be submitted via Editorial Manager. Accepted manuscripts, on average, will be available online within 48 hours in a pre-release format. Molecules and Cells is covered in important abstracting and indexing services including Science Citation Index-Expanded (current Journal Impact Factor 3.8), Scopus (current CiteScore 6.9), PubMed, Current Contents®/Life Sciences, and Chemical Abstract Service. Louise Curtis, Elsevier Senior Vice President, Life Sciences, Social Sciences, Economics, remarked, “We are delighted that KSMCB has selected Elsevier as its partner, and we are proud to publish this well-established, well-run open access journal. It is an excellent complement to the Elsevier molecular and cell biology journal portfolio, expanding our author base into the Korean scientific community. We are committed to providing the best possible support for KSMCB’s mission and community and fostering an international exchange of cutting-edge research.” Notes for editors About Molecules and Cells Molecules and Cells is an international online open access journal devoted to the advancement and dissemination of fundamental knowledge and ground-breaking research in all areas of cellular and molecular biology. Publications cover a broad range of topics of general interest but should be within relevant fields of biology. It is the official journal of the Korean Society for Molecular and Cellular Biology. www.sciencedirect.com/journal/molecules-and-cells About the Korean Society for Molecular and Cellular Biology (KSMCB) The Korean Society of Molecular and Cellular Biology (KSMCB) was founded in 1989. During the last 30 years, KSMCB has grown into one of the largest and most prominent academic societies in the life sciences in Korea. KSMCB serves as a platform for molecular and cellular biologists outside Korea as well, providing them with the opportunity of collaboration and knowledge of cutting-edge research trends. The Society publishes Molecules and Cells, a molecular biology journal with a broad subject coverage and readership, and hosts an annual international conference, a forum for cutting-edge research in all areas of molecular and cellular biology. www.ksmcb.or.kr/eng About Elsevier and society partnerships Elsevier has long-standing partnerships with over 600 learned societies worldwide, helping them to realize their missions and inspire and support their communities. We pride ourselves on consistently delivering outstanding publishing outcomes through strategic insight, reliable finances, global dissemination, embracing open science and open access, and championing the needs of the communities we jointly serve. www.elsevier.com/societies About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses. Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet and Cell; 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details Carolien van der Zanden Senior Marketing Communications Manager, Elsevier c.zanden@elsevier.com Jae Bum Kim Editor-in-Chief, Molecules and Cells jaebkim@snu.ac.kr Company Website https://www.elsevier.com/

November 01, 2023 09:00 AM Eastern Daylight Time

Image

DPH Biologicals, University of Illinois Team Up to Improve Crop Residue Management

DPH Biologicals

• Trials focus on benefits of biologicals for post-harvest stubble control • First-year results unveiled October 30 at international agronomy sciences meeting DPH Biologicals and the University of Illinois Urbana-Champaign (UIUC) announced today a research collaboration validating the impact biologicals make to accelerate decomposition of crop residue, thereby unlocking the adoption of more sustainable and profitable farming practices for United States high-yield, broadacre growers. Starting in spring of 2023, the UIUC Crop Physiology Lab run by Fred Below, Ph.D. and Connor Sible, Ph.D., began researching the impact of microbial solutions in crop residue management including the use of TerraTrove® Residuce®, technology developed by DPH Bio. Residuce is a biodigester, a biological specifically formulated to accelerate the process of plant tissue degradation. “Supporting Dr. Below’s lab is an opportunity to ground-truth the benefits of biodigesters, understand how technologies like Residuce can enable more sustainable and profitable cropping practices and to develop best practice use recommendations supporting our retail and channel partners with high-value, science-verified cropping solutions,” said Alex Cochran, Ph.D., DPH Bio’s Chief Technology Officer. A subset of biofertilizers, biodigester sales are exploding as part of the expanding global biofertility market, projected to reach $3.75 billion USD in sales by 2030, a CAGR of 12.80%, underpinned by market demand for more sustainably-grown food with farmers’ need to offset increasing costs and shrinking profit margins. Residuce, available in a liquid and dry formulation, is currently used on 1.5 million North American acres, a 50% growth rate in the past year. Already, early UIUC trial results indicate improved yields when biodigesters were used with cover crop plantings. Cover crops are typically associated with lower yields, a correlation that has discouraged grower adoption despite the well-known soil health benefits of cover cropping. Using Residuce on an unmanaged cereal rye cover crop partially eliminated the nearly nine-bushel yield penalty average experienced when a cover crop is planted between no-till corn and soybean rotations, according to research presented Monday by UIUC graduate student Darby Danzl at the 2023 ASA, CSSA, SSSA International Annual Meeting, held jointly by the American Society of Agronomy, the Crop Science Society of America and the Soil Science Society of America. The yield penalty was nearly fully eliminated when a fertilizer source was combined with Residuce. Research Focuses on Value-Creation of Biodigesters for Corn, Soybean and Wheat Production With UIUC already a research leader in residue management strategies in broadacre cropping systems, the ongoing field trial collaborations with DPH Bio will focus on further defining the value biodigesters bring to unlocking the value of residue for sustainable agriculture. DPH Bio recently published “ Rethinking Crop Residue Management with Biodigesters,” an analysis of research into crop residue management, includes work already completed by the UIUC crop physiology lab as well as DPH Bio’s field trial results. The UIUC-DPH partnership will expand upon the research and benefits of biodigesters presented in the white paper. Large volumes of crop residue create problems, Sible said, with high-yielding cultivars and practices like no-till, double-cropping and cover cropping generating more residue than growers’ have ever experienced. Today’s average 180-bushel corn crop yields 3.9 tons per acre of corn stover and every additional bushel in yield contributes another 43.7 pounds of stover, according to UIUC research. Growers complain of delayed germination, poor plant stands, nutrients locked up in the decomposing process, increased disease and pest outbreaks from pathogens that overwinter in thick residue layers and yield penalties associated with residue accumulation. Yet, once broken down, residue is an untapped source of nutrients and better soil and crop health. Strategies for accelerating residue degradation are key, Below said. “Residue is nature’s biological. It’s so good for the soil and the plant, and there's a lot of nutrition there. But residue can be your best friend or your worst nightmare,” Below said. “The quicker you can degrade residue, the easier you can plant, the more uniform your crop is going to emerge and the more likely you’re going to get the benefits of that residue.” The next round of joint UIUC-DPH Bio trials will focus on: ● The benefits of biodigesters for cover crop management in no-till corn and soybean. ● Fall versus spring residue management with biodigesters to benefit continuous corn yield. ● Biodigesters value to residue management in a wheat-soybean double crop rotation. Studies conducted in 2023 will be available this winter. The second round of trial results will be available before the 2025 planting season. About DPH Biologicals DPH Biologicals aims to be the industry’s most trusted biologicals provider. We attract, develop and scale technologies improving broad market access and simplifying the grower experience with biologicals. With more than three decades invested into scientific research, field-testing, partner relationships and product development, we’ve built three proven product platforms – BellaTrove® for biocontrols; TerraTrove® for biofertility and biodigesters; and RegenAphex™, a regenerative, plant-based humus extract that serves as a foundation for our flagship biofertilizer SP-1 Classic and a platform for third-party technological development. For more information, visit www.dphbio.com. Contact Details AgTech PR for DPH Bio Georgie Smith georgie@agtechpr.com Company Website http://www.dphbio.com

November 01, 2023 08:30 AM Eastern Daylight Time

Image

CURE ALZHEIMER’S FUND RECEIVES $50,000 GRANT FROM GREATER TOLEDO COMMUNITY FOUNDATION

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund (CureAlz), a non-profit dedicated to funding the most promising research to end Alzheimer’s disease, received a $50,000 grant from the Robert A. Stranahan, Jr. Charitable Advised Fund of the Greater Toledo Community Foundation. This grant represents their largest gift to Cure Alzheimer’s Fund since the Robert A. Stranahan, Jr. Charitable Advised Fund made its first grant to the non-profit in 2016. Through eight years of consecutive giving, the fund has provided $235,000 to CureAlz scientists working to find a cure. “Year after year, we are more encouraged by the progress Cure Alzheimer’s Fund is making to understand Alzheimer’s disease,” said Keith Burwell, President of Greater Toledo Community Foundation. “Our continued philanthropic support provides necessary funding for research that accelerates the discoveries that will eventually tackle Alzheimer’s disease and find a cure.” “The Greater Toledo Community Foundation recognizes the physical, emotional and financial impact this disease has on so many families in its community and around the world and has been a wonderful partner to CureAlz in our mission to find a cure,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Alzheimer’s devastates not just individual patients but their family and community as well. Developing effective, accessible therapies requires deep understanding of the complex causes and pathologies of Alzheimer’s. The scientists CureAlz supports are pursuing vital high-risk, high-reward research to accelerate progress. We are deeply grateful to the Greater Toledo Community Foundation for sharing our goal to end the burden of Alzheimer’s.” It is estimated that more than 6.5 million Americans are currently living with Alzheimer’s disease, a number that is expected to increase rapidly as the Baby Boomer generation continues to age. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimer’s disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones. With the philanthropic support of the Robert A. Stranahan, Jr. Charitable Advised Fund of the Greater Toledo Community Foundation and tens of thousands of other donors, CureAlz has been able to direct more than $180 million to Alzheimer’s disease research since its inception in 2004 and has delivered critical breakthroughs for the research community. About Greater Toledo Community Foundation Greater Toledo Community Foundation is a public charitable organization created by citizens of our community to enrich the quality of life for individuals and families in our area. In existence since 1973, the Foundation has more than 970 individual current funds with assets of approximately $406 million. The Foundation provides philanthropic services for individuals, families, businesses and corporations to meet their charitable giving needs. For more information on the Foundation, visit the organization’s website at www.toledocf.org or follow them on Facebook or LinkedIn. About Cure Alzheimer’s Fund Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, please visit https://www.curealz.org/. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org

November 01, 2023 05:51 AM Eastern Daylight Time

News Release

Perimeter Medical Imaging AI initiates new clinical trial site in Seattle, WA

Perimeter Medical Imaging AI

Adrian Mendes, the CEO of Perimeter Medical Imaging, joined Steve Darling from Proactive with news that the company has initiated an additional clinical trial site at the University of Washington in the Fred Hutch Cancer Center. Perimeter's clinical trial is a multi-center, randomized, two-arm pivotal study that evaluates the investigational Perimeter B-Series Optical Coherence Tomography (OCT) technology. This technology is combined with Perimeter's proprietary ImgAssist AI software and is used during breast conservation surgeries. The core of this innovative approach is the use of ultra-high-resolution, real-time, advanced imaging tools to examine excised tissues at the cellular level, providing crucial insights to surgeons. Mendes emphasized the significance of this additional clinical trial site, as it plays a vital role in gathering valuable data generated during the study. This data will be instrumental in supporting the commercialization of Perimeter's B-Series technology. The company's ultimate goal is to transform cancer surgery by providing advanced technology that not only improves patient outcomes but also helps reduce healthcare costs. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 31, 2023 03:22 PM Eastern Daylight Time

Video

News Release

1606 Corp announces cutting-edge AI-driven CHATCBDW is live and in operation

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news the company has officially unveiled its cutting-edge AI chatbot, ChatCBDW, which represents a significant advancement in the world of CBD products and customer engagement. Lambrecht explained that ChatCBDW has undergone key designs and rigorous testing before being launched and is now live and operational. This innovative chatbot offers a wide range of user-centric features that go beyond the ordinary. One of its standout attributes is its capability to respond to user inquiries and provide comprehensive education on all aspects of CBD. However, ChatCBDW doesn't stop there. It takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This level of innovation empowers customers to make well-informed choices, explore a diverse array of CBD products, and promises an unparalleled shopping experience within the CBD industry. The seamless integration of ChatCBDW with Microsoft Azure is a key component of its capabilities. Microsoft Azure is renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during periods of peak demand, delivering users a consistently responsive and seamless experience throughout their interaction with the chatbot. The company has also announced that Cool Blue Distribution is now a North American licensed reseller of ChatCBDW and is set to engage its network of over 800 CBD retailers immediately. The first direct-to-merchant marketing campaign is scheduled to begin by mid-November 2023, with the goal of generating notable revenue before January 1, 2024. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 31, 2023 03:16 PM Eastern Daylight Time

Video

Introducing the TechClusion Fund

Communication Service for the Deaf

CSD Social Venture Fund, a subsidiary of Communication for the Deaf, is proud to announce the launch of a new funding source for tech startups that prioritize inclusion and accessibility for deaf communities. The TechClusion Fund is a groundbreaking initiative that addresses a common oversight in technology development: accessibility. The fund was created with the intention of accelerating technology built by companies that create accessible products and services that benefit the Deaf community. Over the past 30 years, our society has experienced a rapid evolution in technological advancements. While these advancements generally improve our lives, we often see accessibility features added as an afterthought instead of being built into the original product design. This practice makes the user experience less than ideal for both those who do and do not use these features. “Accessible technology doesn’t just benefit Deaf communities,” explained Rosa Lee Timm, President of CSD Social Venture Fund. “When companies design their products with the needs of Deaf or disabled users in mind, they create a better experience for all users.” The TechClusion Fund was started with the intention of addressing these systemic and prevalent issues in tech by ensuring that entrepreneurs and developers are intentionally creating their products with all end-users in mind. “We expect that the impact of the TechClusion Fund will extend beyond the development of accessible products,” shared Greg Bland, Director of Business Development for CSD Social Venture Fund. “By focusing on startups who hope to have a positive impact on Deaf communities, we will see job creation and more opportunities for economic advancement for Deaf individuals.” Unlike CSD Social Venture Fund’s traditional VC funding, TechClusion is open to all tech-startups operating in the United States and not specifically Deaf-owned businesses. Applicants must demonstrate the following: How their work will positively impact Deaf communities. This can be through hiring Deaf and hard of hearing employees, Deaf ownership, or outlining how their product or service will contribute to deaf communities. A commitment to equitably hire Deaf, BIPOC Deaf, and other Deaf groups for various positions at levels of the company, including C-level positions, as the company grows. A commitment to both their company and TechClusion’s investment. For those who are interested in applying or learning more, you can visit CSD Social Venture Fund’s website or contact Rosa Lee Timm at svf@csdsvf.com for more information. CSD's Social Venture Fund is one of the only venture capital firms and incubators in the world supporting Deaf entrepreneurs and Deaf-owned and operated businesses. CSD SVF provides equity investments to Deaf-led businesses that exemplify CSD’s values: enhancing Deaf economic power, employing Deaf people, and creating social change. CSD SVF is committed to the success of each business, providing not only financial investment, but also access to tools and resources, enabling each Deaf-led business to thrive. Existing portfolio members include Mozzeria, National Deaf Therapy, DeafTax, Bus Door Films, Hands on Travel, Hotsy Totsy Haus, 4Legz All Natural Dog Treats and Lochiel Brewing. For more information, please visit https://csdsvf.com/ and follow us on Facebook, Twitter, Instagram, and LinkedIn. About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the largest Deaf-led social impact organization in the world. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, specifically addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. Contact Details Communication Service for the Deaf Molly Miller +1 315-679-8948 mmiller@csd.org Company Website https://www.csd.org/

October 31, 2023 01:12 PM Eastern Daylight Time

Image

Stay Ahead of Cough, Cold and Flu Season

YourUpdateTV

As the colder months approach, millions of people across the nation are gearing up for the inevitable cough, cold and flu season. Recently, Emergency Room Physician, Dr. Darria Long, conducted a satellite media tour to share tips and advice on how to stay healthy and prepared. A video accompanying this announcement is available at: https://youtu.be/5yVw5AWHbXw As the colder months approach, millions of people across the nation are gearing up for the inevitable cold and flu season. The cough, cold and flu season is marked by a significant increase in the spread of respiratory viruses, which can lead to a surge in illnesses and medical visits. Advanced preparation provides an opportunity to ensure that necessary supplies, medications, and remedies are readily available. Having essential items, like Mucinex 12H, on hand before symptoms strike can make a significant difference. Mucinex 12-Hour relieves chest congestion and thins and loosens mucus. It is clinically proven to last up to 12 hours and provide relief for your chest congestion and make coughs more productive. One dose of Mucinex 12-Hour lasts 3 times longer than other 4-HR medicines helping individuals manage discomfort effectively and get back to their daily activities sooner. Always use over-the-counter products as directed. If symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. Taking better care of ourselves during the cough, cold and flu season is paramount to staying healthy and minimizing the risk of falling ill. Key preventative measures like washing your hands often, covering your nose and mouth with a tissue when you cough or sneeze, and sneezing into your elbow if you don’t have a tissue are extremely effective at preventing the spread of germs. Additionally, maintaining a healthy lifestyle is crucial. Adequate sleep, a balanced diet rich in fruits and vegetables, regular physical activity, and managing stress contribute to a strong immune system. Staying hydrated by drinking plenty of fluids, particularly water and herbal teas, can also help keep our respiratory tract moist and better able to fend off viruses. For more information on how to take care of yourself this cold and flu season, visit Mucinex.com. You can stop by Walmart, Target, your local pharmacy or food retailer to buy Mucinex now ahead of this cough and cold season. BIO: Dr. Darria Long, MD Dr. Darria Long leverages the best of science, to make our lives healthier, better… and easier. By combining her life’s work as an Emergency Room physician and being a mom of two – Dr. Darria has become the nation’s ‘making life better for women’ doctor by helping individuals pave ways to stay present and remain healthy during times of constant distractions and high stress. With a website devoted to distilling health headlines and creating a thriving lifestyle, Dr. Darria shares simple, evidence-based (from western, eastern, and integrative medicine) advice on physical and mental wellness, and the health guidance you’d expect and trust from a close friend. A favored national TV contributor and national bestselling author of Mom Hacks, Dr. Darria is also a TED speaker “How to triage your life like an ER doctor,” and Clinical Assistant Professor at the University of Tennessee. She received her training in emergency medicine at Yale School of Medicine and her MBA from Harvard Business School. A featured regular on CNN, Headline News, NBC, Interview Healthline, Hallmark, Lifetime, Dr. Oz, Thrive Global, Atlanta Small Business Network, Parenting for the future, and many others. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 31, 2023 01:04 PM Eastern Daylight Time

Video

PathAI Announces Research Presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced it will present research underscoring the efficacy of PathExplore’s human interpretable features (HIFs) through three poster presentations at the Society for Immunotherapy of Cancer’s 38 th Annual Meeting on November 1-5 in San Diego, CA. The posters showcase how PathExplore provides high-resolution characterization of the tumor microenvironment (TME) through a standardized panel of HIFs derived from H&E whole slide images across multiple cancer types. Additionally, Incendia Therapeutics will present two posters reporting results that were generated utilizing PathExplore. “Building upon past publications and presentations, we continue to see the utility for histological features of the tumor microenvironment to further our understanding of disease biology, patient prognosis, and therapeutic response, which ultimately may lead to the discovery and implementation of novel biomarkers to advance precision medicine,” explained Mike Montalto, Ph.D., Chief Scientific Officer, PathAI. All three posters demonstrate the correlation between specific HIFs and established molecular measurements of the TME (e.g., gene expression profiles of specific cell populations), as well as specific HIFs and complex molecular signatures (e.g., immune phenotypes) which could better aid in the identification of patients eligible for targeted therapies, or result in the identification of new histology-based biomarkers. Quantifying the effect of microsatellite instability and mismatch repair deficiency on the tumor microenvironment (Poster 73) In this research, PathAI investigated the potential to predict and compare microsatellite stability and mismatch repair subtypes in colorectal and endometrial cancers utilizing PathExplore HIFs. The findings suggest MSS/dMMR tumors may warrant consideration for immunotherapy due to their TME’s similarity to microsatellite instability-high (MSI-H) and tumor mutation burden-high (TMB-H) solid tumors and AI-powered analysis of H&E WSI presents a more accessible and scalable method than current dMMR testing options. This poster will be presented by Judy Chen and Shima Nofallah on Friday, November 3 rd. Poster hall hours are 9 a.m. to 7 p.m. PT. Quantification of tumor infiltrating lymphocytes (TILs) from pathology slides reflects molecular immune phenotypes (Poster 122) In this research, PathAI deployed its PathExplore products on H&E WSI across eight cancer indications to extract HIFs quantifying the TME, including features that represent TIL fractions, densities, and distributions. Analysis revealed statistically significant correlations between TIL-associated HIFs with gene expression of known lymphocyte markers, as well as immune signature scores such as lymphocyte infiltration. These results show the predictive power that TIL-associated HIFs have for identifying immune phenotypes, as well as a promising direction for the discovery of histology-based immune biomarkers. This poster will be presented by Judy Shen on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Deep learning models identify key tumor microenvironment features associated with genetic signatures of UV metagenesis and alkylating agent treatment in melanoma (Poster 110) In this research, PathAI used PathExplore HIFs to investigate the association between TME features and mutational signatures indicative of UV mutagenesis, as well as alkylating agents-induced mutations. The results suggest that quantifying a tumor’s tissue and cellular composition can reveal meaningful information regarding the underlying mutation-driven or treatment-induced changes in the TME, which may have implications for therapy selection. This poster will be presented by Shima Nofallah on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Incendia Therapeutics (formerly known as Parthenon Therapeutics) posters In addition to the posters above, Incendia Therapeutics will present two posters on Friday, November 3 rd reporting results that were generated utilizing PathExplore. One poster (Poster 1287) compares PathExplore HIFs to mIF features and concluded that "TME models are a robust tool to distinguish tissue and cell features from H&E slides, comparable to mlF image analysis, but requiring less effort, time, and expense." In the second (Poster 1497), Incendia Therapeutics leveraged HIFs quantifying lymphocyte densities across cancer epithelium, cancer stroma, and the epithelial-stromal interface (ESI) to characterize barriers to lymphocyte entry into the cancer epithelium across immune phenotypes. More information on these posters can be found at https://www.incendiatx.com Please visit the PathAI booth, 615, to learn more and meet the team, or email us at bd@pathai.com. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2023 10:00 AM Eastern Daylight Time

Cardio Diagnostics Leverages AI To Combat Cardiovascular Disease

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardiovascular disease is the leading cause of death worldwide, accounting for nearly 18 million deaths annually. That amounts to about one-third of all global deaths. Driven by epigenetics and artificial intelligence, what is being referred to as Precision Cardiovascular Medicine could help alleviate the burden of heart disease on patients worldwide. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and detection more precise, is a potential leader in this developing field of medicine. AI-Driven Currently, the risk for cardiovascular disease is assessed using two common lipid-based clinical tests: the Framingham Risk Score and the ASCVD Pooled Cohort Equation. The disease is then detected using several tests, including exercise ECG, coronary computed tomography angiography, cardiac catheterization, cardio magnetic resonance imaging, single-photon emission computed tomography and echocardiography. Cardio Diagnostics was formed to improve detection through further developing and commercializing clinical tests by leveraging artificial intelligence-driven technology to combat cardiovascular disease. With the goal of becoming one of the leading medical technology companies for improving prevention, detection and treatment of cardiovascular disease, the company has developed four patented/patent-pending and proprietary solutions. The first is Cardio Diagnostics’ coronary heart disease risk assessment tool Epi+Gen CHD, a test that predicts the three-year risk for a coronary heart disease (CHD) event – mainly heart attacks. Powered by AI-driven integrated genetic-epigenetics, the tool enables more effective clinical decision-making and earlier interventions. Along with improved survival, the company reports that the tool is associated with up to $42,000 in cost savings per quality-adjusted life year. The second product developed using Cardio Diagnostics’ AI-driven Integrated Genetic-Epigenetic Engine is PrecisionCHD, and the company reports that it is the only epigenetics-based coronary heart disease detection test in the world. A sensitive and non-invasive alternative to exercise and nuclear stress tests, PrecisionCHD is a blood test where a blood sample can be collected at home or in provider settings without the need to wait weeks or months to get tested or the need for fasting or exposure to radiation. Cardio Diagnostics says this test has demonstrated strong clinical value with 80% sensitivity for men and 76% sensitivity for women, compared to the much lower rates of 45% to 68% using exercise ECG, which measures the electrical activity of the heart during physical activity. Cardio Diagnostics’ Actionable Clinical Intelligence platform offers new epigenetic and genetic insights to clinicians prescribing the Epi+Gen CHD and PrecisionCHD tests, while CardioInnovate360 is a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. These solutions can potentially help address the needs of all major healthcare stakeholders. Easing The Burden Cardiovascular disease is a burden on all major stakeholders, including patients, providers, insurers and employers, who can face increased healthcare costs due to heart disease as employees with cardiovascular disease have medical bills that are over twice as high as those without the condition. Additionally, heart disease accounts for about a quarter of all emergency room visits related to chest pain according to the National Center for Biotechnology Information, straining hospital resources and emergency departments that see the sickest of patients. Globally, cardiovascular disease is expected to result in a cumulative output loss of $47 trillion from 2011 to 2030 due to medical costs and productivity losses, according to data compiled by Cardio Diagnostics. While cardiovascular disease is the leading cause of death worldwide, it is in fact highly preventable, with WHO data suggesting that 80% of premature heart attacks and strokes are preventable. That means these costs can be avoided, too. Cardio Diagnostics seems well-positioned to leverage its scalable tests around the world to aid in reducing the incidence of heart attacks and other CHD events. Between their robust product pipeline with tests across the CVD continuum from heart attacks to heart failure combined with strong partnerships with key healthcare stakeholders, there is a defined path to reduce the global impact of heart disease. By proactively identifying and entering multiple international markets to drive global access to Cardio’s technologies, the company seeks to diversify the risks of depending on a single national market and build a sustainable global strategy. This worldwide focus, coupled with a presence in diverse markets, has placed Cardio Diagnostics among the leaders in this growing field of artificial intelligence-powered medicine. For more information on Cardio Diagnostics, visit their website Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website http://www.cardiodiagnosticsinc.com/

October 31, 2023 09:15 AM Eastern Daylight Time

1 ... 80 81 82 83 84 ... 309